Pharmaceuticals Market Research Reports & Industry Analysis

Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.

The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.

The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.

Found 14432 publications
China Pharmaceutical Mfg. Industry Data Report US$ 580.00

This data report provides key statistics and concise analysis on pharmaceutical mfg. industry in China. It presents an overview on pharmaceutical mfg. industry's overall performance for the year 2011 to 2013, and reveals differences in various regions of Mainland China in terms of pharmaceutical mfg. sector, ...

Sep, 2014 29 pages
ICT investment trends in pharmaceuticals - Enterprise ICT spending patterns through to the end of 2015 US$ 2,995.00

... budgets across the core areas of enterprise ICT expenditure: hardware, software, IT services, communications, and consulting. The report illustrates the core technologies enterprises are investing in, including business intelligence, content management, and cloud computing. The survey also highlights the ...

Sep, 2014 57 pages
PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022 US$ 10,995.00

PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022 SUMMARY Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and ... pain market? What differences exist in the current disease management across the 3 NP indications, and across the 7 markets? What are the ...

Apr, 2014 423 pages
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 US$ 10,995.00

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Analysis to 2023 SUMMARY Major depressive disorder (MDD) is one of the most ... 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries ...

May, 2014 322 pages
PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update US$ 10,995.00

PharmaPoint: Hepatitis C Virus - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update SUMMARY Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience ...

May, 2014 381 pages
PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update US$ 10,995.00

PharmaPoint: Epilepsy - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update SUMMARY Epilepsy is a brain disorder characterized by spontaneously occurring ... . Additional unmet needs still exists in terms of safety and efficacy. Will the drugs under development fulfil the unmet needs of the ...

Dec, 2013 306 pages
PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Asthma - US Drug Forecast and Market Analysis to 2023 SUMMARY Asthma accounts for approximately 250,000 deaths around the world ... impact of key events as well the drivers and restraints affecting the US Asthma market. REASONS TO BUY Understand and capitalize by identifying products that ...

Aug, 2014 168 pages
PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Asthma - Japan Drug Forecast and Market Analysis to 2023 SUMMARY Asthma accounts for approximately 250,000 deaths around the ... treatment with the ICS and ICS/LABA therapies. SCOPE Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines ...

Aug, 2014 167 pages
PharmaPoint: Asthma - Current and Future Players US$ 2,995.00

... Future Players SUMMARY GlobalData has released its pharma report, “PharmaPoint: Asthma - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Asthma Market. The report identifies and analyses the key companies ...

Aug, 2014 55 pages
PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Asthma - Australia Drug Forecast and Market Analysis to 2023 SUMMARY Asthma accounts for approximately 250,000 deaths around the world ... , this growth will be fueled mainly by the uptake of the new branded biologic drugs. A dip in sales caused by the Singulair patent expiry in 2012, as well as ...

Aug, 2014 183 pages
PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023 US$ 6,995.00

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023 SUMMARY Asthma accounts for approximately 250,000 deaths around the ... the French, Spanish, and UK markets is attributable to the slightly decreasing prevalence of asthma in this country over the forecast period. . Advair’s active patent on ...

Aug, 2014 218 pages
Cough, Cold and Allergy (Hay Fever) Remedies in Algeria US$ 900.00

Rising disposable income levels supported sales growth in cough, cold and allergy (hay fever) remedies towards the end of the review ... domestic production struggling to meet demand. Euromonitor International's Cough, Cold and Allergy (Hay Fever) Remedies in Algeria report offers a comprehensive guide to the ...

Sep, 2014 23 pages
Thermalin Diabetes, LLC - Product Pipeline Review - 2014 US$ 1,500.00

... , key information and facts, and its locations and subsidiaries The report reviews current pipeline of Thermalin Diabetes, LLC’s human therapeutic ... dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Thermalin Diabetes, LLC’s pipeline products Reasons ...

Sep, 2014 26 pages
tesa Labtec GmbH - Product Pipeline Review - 2014 US$ 1,500.00

... stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the tesa Labtec GmbH’s pipeline products Reasons ...

Sep, 2014 22 pages
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... on the availability and relevance of data for the indicated disease. Scope The report provides brief overview of Shanghai Fudan-Zhangjiang Bio- ... discontinued pipeline projects Latest company statement Latest news and deals relating to the Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.’s pipeline ...

Sep, 2014 30 pages
Orphagen Pharmaceuticals, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Orphagen Pharmaceuticals, Inc.’s pipeline products Reasons to ...

Sep, 2014 24 pages
NGM Biopharmaceuticals, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the NGM Biopharmaceuticals, Inc.’s pipeline products Reasons ... Assess the growth potential of NGM Biopharmaceuticals, Inc. in its therapy areas of focus Identify new drug targets and therapeutic classes in the ...

Sep, 2014 23 pages
Kaketsuken K.K. - Product Pipeline Review - 2014 US$ 1,500.00

Summary Global Markets Direct’s, ‘Kaketsuken K.K. - Product Pipeline Review - 2014’, provides an overview of the Kaketsuken K.K.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Kaketsuken K.K.’s, complete ...

Sep, 2014 26 pages
Generic and Innovative Drugs Market in Ukraine 2014. Development Forecasts for 2014-2019. US$ 1,330.00

... procedures and upcoming changes or estimate demand or growth potential of this market – they will find the informational support needed in this valuable ... to launch a new business or add a new product line. Generic and innovative drugs market in Ukraine, development forecasts for 2014-2019 is typically ...

Aug, 2014 100 pages
Generic and Innovative Drugs Market in Russia 2014. Development Forecasts for 2014-2019. US$ 1,330.00

... and business consultants, as well as research specialists and analysts. Generic and innovative drugs market in Russia, Development forecasts for 2014-2019 is useful ... regulations (and impending changes) that apply to the manufacture and marketing of these new and sought after medicines. Discover what the ...

Aug, 2014 120 pages
Global Antibiotics Market 2014-2018 US$ 2,500.00

... , fungi, and parasites but are not effective against viruses. Antibiotics either block vital processes in bacteria, kill the bacteria, or halt ... , Phenicols, Quinolones, Sulfonamides, Tetracyclines, and Others. TechNavio's report, the Global Antibiotics Market 2014-2018, has been prepared based on an in-depth ...

Sep, 2014 96 pages
India Probiotic Market Forecast and Opportunities, 2019 US$ 1,800.00

... , probiotic animal feeds are also becoming very popular among Indian farmers to feed their cattle. According to “India Probiotic Market Forecast & Opportunities, 2019”, India’s probiotic market is projected to grow at a CAGR of around 19% till 2019. The market has been segmented into Probiotic functional ...

Sep, 2014 159 pages
Austria Pharmaceuticals and Healthcare Report Q4 2014 US$ 1,295.00

... updates BMI View: BMI has upwardly revised its pharmaceutical and healthcare forecasts for Austria, reflecting the country's improving economic prospects ... country had limited effect in both volume and value sales of pharmaceuticals, indicating its attractiveness even as the European economy remains subdued ...

Sep, 2014 68 pages
Tolvaptan - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Tolvaptan indications: Treatment of hypervolemic and euvolemic hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion and congestive heart failure innovator: Otsuka Pharm (Samsca); Aspen (Samsca) Country ...

Sep, 2014
Tolvaptan - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and results This report covers: International Nonproprietary Name: Tolvaptan indications: Treatment of hypervolemic and euvolemic hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion and congestive heart failure innovator: Otsuka Pharm (Samsca); Aspen (Samsca) Country ...

Sep, 2014
Tolvaptan - Comprehensive patent search US$ 6,200.00

... and results This report covers: International Nonproprietary Name: Tolvaptan indications: Treatment of hypervolemic and euvolemic hyponatraemia secondary to syndrome of inappropriate antidiuretic-hormone secretion and congestive heart failure innovator:Otsuka Pharm (Samsca); Aspen (Samsca) Country ...

Sep, 2014
Simeprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... and results This report covers: International Nonproprietary Name: Simeprevir indications: Treatment of chronic hepatitis C infection in combination with Peginterferon alfa and Ribavirin, or with Sofosbuvir and optionally Ribavirin innovator: Janssen Pharm (Olysio, Galexos) Country Coverage: ...

Sep, 2014
Simeprevir - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... and results This report covers: International Nonproprietary Name: Simeprevir indications: Treatment of chronic hepatitis C infection in combination with Peginterferon alfa and Ribavirin, or with Sofosbuvir and optionally Ribavirin innovator: Janssen Pharm (Olysio, Galexos) Country Coverage: Albania ...

Sep, 2014
Mirabegron - Comprehensive patent search US$ 6,201.00

... , save searches and results This report covers: International Nonproprietary Name: Mirabegron indications: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency innovator:Astellas (Myrbetriq, Betmiga) Country coverage: The In-depth search contains ...

Sep, 2014
Ledipasvir - Comprehensive patent search US$ 7,500.00

... searches and results This report covers: International Nonproprietary Name: Ledipasvir indications: Treatment of chronic HCV infection in combination with Sofosbuvir innovator:Gilead Country coverage: The In-depth search contains patents from territories that are individually verified and monitored ...

Sep, 2014
Elvitegravir - Patent, Extension and Data Exclusivity Expiry Snapshot (9 countries) US$ 600.00

... results This report covers: International Nonproprietary Name: Elvitegravir indications: Treatment of HIV-1 infection in combination with Cobicistat, Emtricitabine and Tenofovir disoproxil fumarate, or Ritonavir-boosted protease inhibitors or other antiretrovirals innovator: Gilead (Stribild); Gilead ( ...

Sep, 2014
Elvitegravir - Patent, Extension and Data Exclusivity Expiry Snapshot (50 countries) US$ 1,400.00

... results This report covers: International Nonproprietary Name: Elvitegravir indications: Treatment of HIV-1 infection in combination with Cobicistat, Emtricitabine and Tenofovir disoproxil fumarate, or Ritonavir-boosted protease inhibitors or other antiretrovirals innovator: Gilead (Stribild); Gilead ( ...

Sep, 2014
Elvitegravir - Comprehensive patent search US$ 7,500.00

... This report covers: International Nonproprietary Name: Elvitegravir indications: Treatment of HIV-1 infection in combination with Cobicistat, Emtricitabine and Tenofovir disoproxil fumarate, or Ritonavir-boosted protease inhibitors or other antiretrovirals innovator:Gilead (Stribild); Gilead (Vitekta); ...

Sep, 2014
Aflibercept - Comprehensive patent search US$ 9,300.00

... of neovascular wet age-related macular degeneration; Treatment of macular edema following central retinal vein occlusion; Treatment of metastatic colorectal cancer that is resistant to or has progressed following an Oxaliplatin-containing regimen in combination with 5-Fluorouracil, Leucovorin and Irinotecan ...

Sep, 2014
Abatacept - Comprehensive patent search US$ 9,300.00

... indications: Treatment of adult rheumatoid arthritis, optionally in combination with DMARDs optionally other than TNF antagonists; Treatment of juvenile idiopathic arthritis, optionally in combination with Methotrexate; Treatment of juvenile rheumatoid arthritis innovator:Bristol Myers Squibb (Orencia) ...

Sep, 2014
Zosano, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Zosano, Inc.’s pipeline products ... drug targets and therapeutic classes in the Zosano, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Sep, 2014 23 pages
Recepta Biopharma S.A. - Product Pipeline Review - 2014 US$ 1,500.00

... and its locations and subsidiaries The report reviews current pipeline of Recepta Biopharma S.A.’s human therapeutic division and enlists all their major ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Recepta Biopharma S.A.’s pipeline products ...

Sep, 2014 26 pages
Q Chip Ltd. - Product Pipeline Review - 2014 US$ 1,500.00

... business description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Q Chip Ltd.’s human therapeutic ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Q Chip Ltd.’s pipeline products ...

Sep, 2014 21 pages
Genextra S.p.a. - Product Pipeline Review - 2014 US$ 1,500.00

Genextra S.p.a. - Product Pipeline Review - 2014 SUMMARY Global Markets Direct’s, ‘Genextra S.p.a. - Product Pipeline Review - 2014’, provides an overview of the Genextra S.p.a.’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic ...

Sep, 2014 23 pages
Arthrogen BV - Product Pipeline Review - 2014 US$ 1,500.00

Arthrogen BV - Product Pipeline Review - 2014 SUMMARY Global Markets Direct’s, ‘Arthrogen BV - Product Pipeline Review - 2014’, provides an overview of the Arthrogen BV’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental ...

Sep, 2014 21 pages
Global Erectile Dysfunction Drugs Market 2014-2018 US$ 2,500.00

... and effective therapies. TechNavio's analysts forecast the Global Erectile Dysfunction Drugs market to decline at a CAGR of 4.47 percent over the period 2013- ... Surgery, Injection Therapies, and Testosterone Replacement Therapy. To calculate the market size, the report considers the revenue generated from the ...

Sep, 2014 77 pages
Pediatric Drug Development - Regulatory Challenges and Commercial Opportunities US$ 2,995.00

... Pediatric vaccines Key Reasons to Purchase Reviews the current regulatory landscape and helps sponsors to understand the potential impact of FDA SIA regulations ... plans; Identifies the key challenges associated with pediatric drug development and the ways to overcome these hurdles; Assesses what issues ...

Jul, 2014 64 pages
Adaptive Licensing - A Holistic Approach to Drug Development and Regulation US$ 2,995.00

... and registries. Data from ongoing RCTs, and the more robust data from post-license surveillance studies are used to determine full ... and political changes will be necessary to realize the full potential of AL. Scope Adaptive Licensing: Overview Introduction A Declining Industry – How AL can tackle issues ...

Jul, 2014 79 pages
Global Cancer Vaccines Market & Pipeline Analysis US$ 2,400.00

... present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into ... Pipeline by Phase, Indication, Company & Country Global Cancer Vaccine Clinical Pipeline: 289 Vaccines Marketed Cancer Vaccines: 12 Vaccines Regulatory Framework for ...

Sep, 2014 864 pages
Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Review, H2, 2014 Summary GlobalData's clinical trial report, “Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H2, 2014' provides data ... of trials for the key drugs for treating Coronary Artery Disease (CAD) (Ischemic Heart Disease). This report is built using data and ...

Aug, 2014 100 pages
Chronic Thromboembolic Pulmonary Hypertension Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Chronic Thromboembolic Pulmonary Hypertension Global Clinical Trials Review, H2, 2014' provides data ... status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Chronic ...

Aug, 2014 99 pages
Chronic Heart Failure Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Clinical Trials Review, H2, 2014' provides data on the Chronic Heart Failure clinical trial scenario. This report provides elemental information and data ... across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also ...

Aug, 2014 102 pages
Alzheimer's Disease Drug Pipeline, Diagnostics and Biomarkers: New Developments, Growth Areas and Opportunities US$ 3,016.00

... of the drug development pipeline relating to Alzheimer's disease, which has been analysed alongside commercially available or developmental minimally-invasive AD diagnostics and ... studies involving AD patients (and those with (presumed) early-stage disease) and studies published over the last five year, 40,000 ...

Sep, 2014 185 pages
Global Hepatitis B Vaccines Market 2014-2018 US$ 2,500.00

... transient serum sickness-like syndrome, and membranous glomerulonephritis. Perinatal transmission of hepatitis B virus is the most common mode of infection spread. Age of a person ... the present scenario and the growth prospects of the Global Hepatitis B Vaccines market for the period 2014-2018. To calculate the ...

Aug, 2014 91 pages
The US Anti Cancer Drug Market Outlook to 2018 - Demand of Oral Drugs to Drive Growth US$ 900.00

... growth rate can be attributed to an increasing number of drugs being approved by the United States Food and Drug Association along with the increasing ... held a market share of ~% and recorded sales of USD ~ million. The US Anti Cancer Drug Market is expected to grow over the period at a CAGR of 29.4% with ...

Jul, 2014 144 pages
1 2 3 4 5 >
Skip to top